CELESTIAL

Celestial Biolabs Limited has informed the Exchange about Proceedings of Annual General Meeting held on 30-Sep-2022

Celestial Biolabs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 28-Sep-2022 to 30-Sep-2022 for the purpose of Meeting.

Celestial Biolabs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 28-Sep-2022 to 30-Sep-2022 for the purpose of Meeting.

Celestial Biolabs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 28-Sep-2022 to 30-Sep-2022 for the purpose of Meeting.

The Exchange has sought clarification from Celestial Biolabs Limited with respect to announcement dated 03-Sep-2022 informing about Appointment.On the basis of aforesaid announcement, the Company is required to provide/clarify the following: 1. Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority The response of the company is awaited.

Celestial Biolabs Limited has informed the Exchange about appointment of Arvind Deviprasad Sharma as Chief Financial Officer of the company w.e.f. 02-Sep-2022

Celestial Biolabs Limited has informed the Exchange about resignation of Amit Kumar Singh as Chief Financial Officer of the company w.e.f. 02-Sep-2022

Celestial Biolabs Limited has informed the Exchange about change in designation of Amit Kumar Singh as Managing Director of the company w.e.f. 02-Sep-2022, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting

Celestial Biolabs Limited has informed the Exchange about appointment of Gangadharuni Durga Narasimha Kumar as Independent Director of the company w.e.f. 02-Sep-2022, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting

Celestial Biolabs Limited has informed the Exchange about appointment of Prabhakar Korada as Independent Director of the company w.e.f. 02-Sep-2022, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting

Celestial Biolabs Limited has informed the Exchange about appointment of Rakle Mathur Nath as Independent Director of the company w.e.f. 02-Sep-2022, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 02-Sep-2022 to consider financial statements for the period ended March 2022

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 02-Sep-2022 to consider financial statements for the period ended December 2021

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 02-Sep-2022 to consider financial statements for the period ended September 2021

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 02-Sep-2022 to consider financial statements for the period ended June 2021

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 01-Sep-2022 to consider financial statements for the period ended March 2021

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 01-Sep-2022 to consider financial statements for the period ended December 2020

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 01-Sep-2022 to consider financial statements for the period ended September 2020

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 01-Sep-2022 to consider financial statements for the period ended June 2020

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 30-Aug-2022 to consider financial statements for the period ended September 2019

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 30-Aug-2022 to consider financial statements for the period ended March 2020

Celestial Biolabs Limited has informed the Exchange about Board Meeting held on 30-Aug-2022 to consider financial statements for the period ended December 2019

Celestial Biolabs Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018 for the quarter ended 30th June, 2022

Celestial Biolabs Limited has informed the Exchange about Scrutinizer report of Annual General Meeting held on 22-Jun-2022

Celestial Biolabs Limited has informed the Exchange about Voting results of Annual General Meeting held on 22-Jun-2022

Celestial Biolabs Limited has informed the Exchange about Proceedings of Annual General Meeting held on 22-Jun-2022

Celestial Biolabs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 20-Jun-2022 to 22-Jun-2022 for the purpose of Meeting.

Celestial Biolabs Limited has informed the Exchange about appointment of M Surendra & Associates as Statutory Auditor of the company

Celestial Biolabs Limited has informed the Exchange about appointment of Sada Naga Latha as company secretary and Compliance Officer of the company.

Celestial Biolabs Limited has informed the Exchange about appointment of Mrs.Sada Naga Latha as Company Secretary and compliance officer of the company

Celestial Biolabs Limited has informed the Exchange about Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2022

Celestial Biolabs Limited has informed the Exchange about change of registered office address of the Company

Members of the Exchange are hereby informed that the Exchange on November 11, 2020 has issued public notice in the newspaper for proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/Corporate Announcements).

Celestial Biolabs Limited has informed the Exchange regarding Resignation of Mr Hardeep Choudhary as Company Secretary & Compliance Officer of the company w.e.f. November 05, 2019.

The Exchange has sought clarification from Celestial Biolabs Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. The response of the Company is awaited.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

Significant movement in price has been observed in Celestial Biolabs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Celestial Biolabs Limited has submitted their response.

Significant movement in price has been observed in Celestial Biolabs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Celestial Biolabs Limited has informed the Exchange regarding Disclosure of Related Party Transactions on a standalone basis for the year ended March 31, 2019.

CELESTIAL: Celestial Biolabs Limited had informed the Exchange regarding Appointment of Mr Hardeep Choudhary as Company Secretary & Compliance Officer of the company w.e.f. Jun 04, 2019. On basis of above the Company was required to clarify following: 1. Whether intimated in 24hrs 2. Brief profile (in case of appointment) The response of the Company is attached.

Celestial Biolabs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Celestial Biolabs Limited has informed the Exchange regarding Appointment of Mr Hardeep Choudhary as Company Secretary & Compliance Officer of the company w.e.f. Jun 04, 2019. On basis of above the Company is required to clarify following: 1. Whether intimated in 24hrs2. Brief profile (in case of appointment)The response of the Company is awaited.

The Exchange has sought clarification from Celestial Biolabs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. No Segment Reporting. -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -3. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Celestial Biolabs Limited has informed the Exchange regarding Appointment of Mr Hardeep Choudhary as Company Secretary & Compliance Officer of the company w.e.f. Jun 04, 2019.

Celestial Biolabs Limited has informed the Exchange regarding Reasons for Delayed/Non-submission of Financial Results.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

The Exchange had sought clarification from Celestial Biolabs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Standalone limited review report not submitted. The response of the Company is enclosed.

The Exchange has sought clarification from Celestial Biolabs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone limited review report not submitted. The response of the Company is awaited.

Celestial Biolabs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.